Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galena Biopharma GALE

Healthcare Biotechnology
"Galena Biopharma is a biopharmaceutical company. Its main activity is the development and commercialization of hematology and oncology therapies. Its pipeline includes products targeting hematology diseases, breast cancer, gastric cancer, and gynecological cancer. The company’s cancer immunotherapy consists of two areas: prevention of cancer reoccurrence and primary prevention of invasive... see more

Recent & Breaking News (NDAQ:GALE)

Equity Price Movement at a Glance - Research on Gladstone Commercial, Liquidity Services, Galena Biopharma and Hovnanian Enterprises

Accesswire November 16, 2015

Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on Its Clinical Development Programs With Planned Divestiture of the Commercial Business

GlobeNewswire November 9, 2015

Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting

GlobeNewswire November 9, 2015

Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire November 6, 2015

Galena Biopharma Appoints Bijan Nejadnik, M.D., as Executive Vice President and Chief Medical Officer

GlobeNewswire October 30, 2015

Galena Biopharma to Report Third Quarter Financial Results and Provide Business Update on Monday, November 9, 2015

GlobeNewswire October 26, 2015

Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax(TM) Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences

GlobeNewswire October 22, 2015

Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

GlobeNewswire September 30, 2015

Galena Biopharma Presents Positive GALE-301 Phase 2a Clinical Trial Data at the European Cancer Congress 2015

GlobeNewswire September 28, 2015

Galena Biopharma to Present GALE-301 Phase 2a Clinical Trial Data at the European Society for Medical Oncology (ESMO) European Cancer Congress 2015

GlobeNewswire September 14, 2015

Galena Biopharma to Present at Two Upcoming Healthcare Investment Conferences

GlobeNewswire September 1, 2015

Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty

PR Newswire August 31, 2015

Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction of Cardiac Toxicity Monitoring for NeuVax(TM) PRESENT Trial

GlobeNewswire August 24, 2015

Galena Biopharma Reports Second Quarter 2015 Financial Results

GlobeNewswire August 6, 2015

MonoSol Rx Partner Galena Biopharma Launches Zuplenz(R) (Ondanestron) Oral Soluble Film

GlobeNewswire August 5, 2015

Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film

GlobeNewswire July 29, 2015

Galena Biopharma to Report Second Quarter Financial Results on Thursday, August 6, 2015

GlobeNewswire July 28, 2015

Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress

GlobeNewswire June 15, 2015

Galena Biopharma to Present at the Sachs Immuno-Oncology BD&L and Investment Forum

GlobeNewswire May 28, 2015

Galena Biopharma Announces Publication of Two Abstracts at the 2015 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 27, 2015